EverSource Wealth Advisors’s Aquestive Therapeutics AQST Stock Holding History

EverSource Wealth Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17K	Sell	281 -1,681	-86%	-$7.07K	﹤0.01%	3918
2026 Q1	$8.14K	Buy	1,962 +1,684	+606%	+$6.83K	﹤0.01%	3023
2025 Q4	$1.8K	Hold	278	–	–	﹤0.01%	3538
2025 Q3	$1.55K	Hold	278	–	–	﹤0.01%	3598
2025 Q2	$920	Buy	278 +134	+93%	+$384	﹤0.01%	3757
2025 Q1	$418	Buy	+144	New	+$436	﹤0.01%	3516

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

EverSource Wealth Advisors's AQST Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Aquestive Therapeutics (AQST) stake by 86% in Q2 2026, selling an estimated $7.07K and leaving 281 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3918.

EverSource Wealth Advisors first reported a position in AQST in Q1 2025 and has held it in 6 quarters since. The position peaked at $8.14K in Q1 2026. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

EverSource Wealth Advisors held 281 shares of Aquestive Therapeutics worth $1.17K as of Q2 2026.
EverSource Wealth Advisors sold 1,681 Aquestive Therapeutics shares in Q2 2026, an estimated $7.07K.
Aquestive Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3918 holding.
EverSource Wealth Advisors first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 6 quarters since.
EverSource Wealth Advisors's Aquestive Therapeutics position peaked at $8.14K in Q1 2026.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.